Review Article

Type 2 Innate Lymphoid Cells: Friends or Foes—Role in Airway Allergic Inflammation and Asthma

Abbas Pishdadian,1 Abdol-Reza Varasteh,2 and Mojtaba Sankian1

1 Immunology Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2 Immuno-Biochemistry Lab, Allergy Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Correspondence should be addressed to Mojtaba Sankian, sankianm@mums.ac.ir

Received 15 June 2012; Accepted 24 September 2012

Academic Editor: Georgia Hardavella

Copyright © 2012 Abbas Pishdadian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Innate-like lymphocytes (ILLs) and innate lymphoid cells (ILCs) are two newly characterized families of lymphocytes with limited and no rearranged antigen receptors, respectively. These soldiers provide a first line of defense against foreign insults by triggering a prompt innate immune response and bridging the gap of innate and adaptive immunity. Type 2 innate lymphoid cells (ILCs2) are newly identified members of the ILC family that play a key role in type 2 immune responses by prompt production of type 2 cytokines (especially IL-5 and IL-13) in response to antigen-induced IL-25/33 and by recruiting type 2 “immune franchise.” Regarding the two different roles of type 2 cytokines, helminth expulsion and type 2-related diseases, here we review the latest advances in ILC2 biology and examine the pivotal role of resident ILCs2 in allergen-specific airway inflammation and asthma.

1. Introduction

Currently, it is widely accepted that the innate immune system is not just a simple physical barrier to keep intruders out, but also a director of the immune system. This system not only recognizes and responds to foreign insults as an independent immune system, but also has an indisputable role in triggering, directing, and regulating adaptive immunity. To do so, it needs several cell types to be executive cells of innate systems. Hence, the study of these cells’ biology, molecular mechanisms, and interactions has been an interesting area of research since their discovery. Identification of a new innate cell type, innate lymphoid cells, to immune system study had a great impact on our understanding of how the immune system works in physiologic and pathologic situations. In this paper we will review the biology of innate and innate-like cell families and examine type 2 innate lymphoid cells in details, focusing on their role in asthma and other airway inflammatory disorders.

2. Innate-Like Lymphocytes (ILLs)

Several cell types belong to the innate arm of the immune system. All these cells are originally myeloid/monocyte or lymphoid derived. Eosinophils, basophils, mast cells, neutrophils, monocytes, macrophages, and dendritic cells are myeloid/monocyte derivatives of innate cells. Members of this family have no antigen-specific receptors, which defines them as part of innate immunity, and some share both innate and adaptive immune characteristics.

The other member of the innate cell family, lymphoid derived, can be divided into two groups: innate-like lymphocytes (ILLs) [1] and innate lymphoid cells (ILCs) [2].

Innate-like lymphocytes (ILLs) have rearranged antigen-specific receptors with limited diversity and tissue distribution. They are incapable of recognizing and responding to antigens as specifically and powerfully as adaptive cells. For this reason, they provide a first line of defense against foreign invaders. This rapid and innate-like response bridges
a gap between innate and adaptive immunity. Members of this innate-like lymphocyte (ILL) family include mucosal-associated invariant T cells (MAITs) [3–6], invariant natural killer T cells (iNKTs) [7–10], γδ T cells (Tγδ) [11–16], marginal zone B cells (MZB) [17–20], and B1-B cells [21–28]. The biology and function of the ILL family are summarized in Table 1.

3. Innate Lymphoid Cells (ILCs)

The term “innate lymphoid cells” (ILCs) generally refers to an innate cell population with common phenotypic and functional features. Unlike adaptive immune cells, ILCs lack rearranged antigen-specific receptors and therefore are able to react promptly to a wide range of signals. They also have indisputable roles in tissue homeostasis, lymphoid tissue formation, and tissue repair. The ILC family may arise from a common progenitor, but members show three functionally distinct features. These three subsets include natural killer cells (cytotoxic ILCs) [29–35], ILCs with the retinoic acid (RA) receptor-related orphan receptor (RoR) γt transcription factor (RoRγt+ ILCs) [36–39], and type 2 ILCs (ILCs2) [2].

The biology and functions of the ILC family are summarized in Table 2. In this paper, we focus mainly on type 2 ILCs; therefore details about the other two members of ILC family are more complete than those of type 2 ILCs in Table 2.

4. Type 2 Innate Lymphoid Cells (ILCs2)

Type 2 innate lymphoid cells (ILCs2) consist of a heterogeneous cell population that shares phenotypic features and also depends on the common γ chain (γc) of the IL-2 receptor and the transcription repressor Id2 [2]. These are divided into five categories (Table 3): natural helper cells (NHCs), nuocytes, type 2 innate helper cells (Ih2), type 2 innate lymphoid cells (ILCs2), and multipotent progenitor population type 2 (MPPtype2) cells.

4.1. Discovery and Naming. In 2001, a non-B, non-T, non-NK lymphoid cell type was described that released the type 2 cytokines IL-4, IL-5, and IL-13 in response to IL-25 (IL-17E) administration in mice [40]. These cells were RAG independent and γ chain dependent. A decade later, several research groups [42, 50, 53] simultaneously reported the same populations (Lin- scα1+ Thy1+ T1/T2+), but named them differently. All these cells, which are at the final stage of differentiation, produce IL-5 and IL-13 in response to IL-25 and IL-33 (IL-1-like cytokine). These cells were first identified in mice and named natural helper cells (NHCs), in view of their ability to help B1 cells produce antibody [42], nuocytes [50], in view of their IL-13 production (nu = the 13th letter of the Greek alphabet), and type 2 innate helper cells (Ih2) [53]. Nuocytes and Ih2 cells have similar surface markers, with the exception of Ih2 cells being Sca-1 negative, suggesting a close relationship between them.

Similar cell populations with surface markers CD161 and CRTH2, a high affinity PGD2-R, were described in human, which were in their final differentiation stage [55]. It is not clear whether these different reported cell types are truly the same or belong to distinct populations. These cells were recognized by IL-13- and IL-4-green fluorescent protein (GFP) reporter mice and selective-deficient mice.

Another IL-25 responsive type 2 cytokine producer of the ILC2 family is able to differentiate into both monococyte/macrophage and myeloid lineages. These are termed multipotent progenitor population type 2 (MPPtype2) cells [56]. All these cell types have been described in other studies [43–45, 51, 52]. These similar cell populations that are distinct from other innate cell types, especially in surface phenotype (CCR3− CD49b− FCRγIR− Lin−), are categorized as new members of the innate lymphoid cell family. The biology and functions of the ILC2 family are summarized in Table 3.

4.2. Tissue Distribution. Natural helper cells (NHCs) were first observed in fat-associated lymphoid clusters (FALCs) of the intestinal mesentery, in fatty deposits in the peritoneal cavity, and surrounding the kidneys [42]. In another study, it was found that NHCs are also resident in lung tissue of mice [2]. Nuocytes were identified in mesenteric lymph nodes (mLNs), spleen, intestine, and in low abundance in peripheral blood [50]. Type 2 innate helper cells (Ih2) have a broad tissue distribution but are abundant in mLNs, liver, and spleen [53].

MPPtype2 cells are mostly found in mLNs and gut-associated lymphoid tissues (GALTs), such as cecal and Peyer’s patches [56]. Human type 2 innate lymphoid cells (ILCs2) are present in gut and lungs of human fetus and adult, palatine tonsils, and peripheral blood of human adults [55]. ILCs2 are more abundant in fetus (0.2% in lung and up to 2% in intestines) than adult (less than 0.1% of human CD45+ cells in tissues and 0.01–0.03% in peripheral blood) [55].

4.3. Developmental Origins and Effective Factors. The questions about the developmental origins of the ILC2 family are not fully answered but some progenitors have been proposed (reviewed in [43]): these are (1) the common lymphoid progenitor (CLP), which may have the potential to differentiate directly to the ILC2 cell type; (2) ILC2 cells, which may have their own distinct progenitor that may arise from CLPs; (3) MPPtype2 cells, which possess the capacity to generate multiple lineages; myeloid/monocytic/lymphoid in two potent ways: MPPtype2 cell is a homogeneous population in which each individual cell can generate multiple lineages, or MPPtype2 cells are heterogeneous and consist of different progenitors [43]. Recent study revealed that nuocytes are derived from the CLP in bone marrow [52]. They could also result from a pro-T cell in the DN1/DN2 developmental stage [52]. These results indicate that ILC2 cells are more closely related to T cells than any other immune cells. Fresh blood-separated human ILCs2 show more plasticity than tissue-derived ILCs2 [55]. Using RAG-1/ROSA26 (YFP)
Table 1: Innate-like lymphocytes (ILLs) family.

<table>
<thead>
<tr>
<th>Cell type</th>
<th>Date of discovery and naming in the first publish</th>
<th>Main development location</th>
<th>Major transcription factors and molecules needed for development</th>
<th>Anatomical locations</th>
<th>Developmental stage that derived from</th>
<th>Major cytokines produced by cells</th>
<th>Major stimulating cytokines</th>
<th>Activator and profector cells</th>
<th>Antigen receptor</th>
<th>Ligands</th>
<th>Major surface markers</th>
<th>MHC/MHC-like restriction</th>
<th>Major functions and pathology</th>
<th>Antimicrobial defense mechanisms</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>MAIT</td>
<td>(i) Porcelli et al. 1993 [3] (ii) Tilloy et al. 1999 [4]</td>
<td>Thy mus</td>
<td>PIZF (ZBTB16) in human</td>
<td>(i) Gut lamina propria (ii) Liver (human) (iii) Blood (few numbers)</td>
<td>Late double negative (DN)</td>
<td>IL-4 IL-5 IL-10 IL-17 IFN-γ TNF-α</td>
<td>IL-1β</td>
<td>(i) B cells (ii) Gut normal flora</td>
<td>TCRα/β Vα14 (mouse) Vα24 (human)</td>
<td>Hydrophobic molecules</td>
<td>MR1 (class Ib) restriction</td>
<td>(i) Possible regulation of inflammation in autoimmune disorders (ii) Regulation of IgA production in gut (iii) Intestinal homeostasis (iv) CNS pathology</td>
<td>(i) Cytokine production (ii) Cellular recruitment and recalling (iii) Cytotoxicity (Fas, granzymes)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>INKT</td>
<td>(i) In mouse: Koskiet et al. 1990 [7] (ii) In human: Porcelli et al. 1993 [3]</td>
<td>Thy mus</td>
<td>PIZF SLAM</td>
<td>Peripheral lymph tissues such as liver, spleen, and lymph nodes</td>
<td>Double positive (DP) (pro-T)</td>
<td>IL-4 IL-10 IL-12 IL-23 IL-33 TGIF-β</td>
<td>APCs</td>
<td>TCRα/β Vα14 (mouse)</td>
<td>Glycolipids especially α-Gal-Cer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>γδ T cell</td>
<td>(i) Saito et al. 1984 [11] (ii) Samuelson et al. 1985 [12]</td>
<td>Thy mus</td>
<td>Sex13 Id Egr-1</td>
<td>(i) Epiderm (ii) Mucosal tissues (iii) Blood (few numbers)</td>
<td>DN2</td>
<td>IL-17 IFN-γ TNF-α</td>
<td>IL-2 IL-7 IL-21</td>
<td>(i) Mostly by antigens directly (ii) APCs (less common)</td>
<td>TCR γδ</td>
<td>Mostly nonpeptidic self and non-self antigens</td>
<td>NKR: KIRs and NKG2A, C, D, TLRs, CCR7, CD16, CD226, MHC II, cytokine receptors</td>
<td>(i) Mostly no need to MHC restriction (direct recognition) (ii) MHC/MHC-like restriction (less common)</td>
<td>(i) Cytokine production (ii) Cellular recruitment and recalling (iii) Cytotoxicity (Fas, granzymes, perforin)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MZB</td>
<td>MacLennan et al. 1982 [17]</td>
<td>Spleen marginal zone</td>
<td>BAFF Ptok-2 Notch2</td>
<td>(i) Spleen (ii) Blood (few numbers) (iii) Few numbers in Peyer’s patches and lymph node subcapsular sinus</td>
<td>T1/T2 (immature B cell)</td>
<td>IL-6 IL-10 IFN-γ</td>
<td>IL-7 IL-21</td>
<td>(i) APCs (ii) Mostly T independent (iii) Directly by antigen (iv) T dependent (less common)</td>
<td>BCR IgM IgD</td>
<td>Mostly nonpeptidic antigens</td>
<td>CD1, CD9, CD27, CD36, CD11b, GP65, TLRs, S1P1, MHC II, FC-like receptors, CD23</td>
<td>(i) Immunity against blood-borne infections (ii) Immunity against encapsulated bacteria (iii) Response to autoantibodies derived from senescence</td>
<td>IgM and IgG3 production</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

[3–6] [7, 11–16] [17–20]
### Table 1: Continued.

<table>
<thead>
<tr>
<th>Cell type</th>
<th>Date of discovery and naming in the first publication</th>
<th>Main development location</th>
<th>Major transcription factors and molecules needed for development</th>
<th>Developmental stage that derived from common progenitor</th>
<th>Developmental location</th>
<th>Major cytokines produced by cells</th>
<th>Major stimulating cytokines</th>
<th>Activator and proliferator cells</th>
<th>Antigen receptor</th>
<th>Ligands</th>
<th>Major surface markers</th>
<th>Major functions and pathology</th>
<th>Antimicrobial defense mechanisms</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>B1-B cell</td>
<td>(i) Gronovicz and Coutinho 1975 [21] (ii) Hayakawa et al. 1983 [22]</td>
<td>Firstly in BM, then located in tissue</td>
<td>BAFF, NFATc1, Siglec-G</td>
<td>T1/T2 (immature B cell) IL-6 IL-10 TNF-α</td>
<td>IL-6</td>
<td>IL-5</td>
<td>(i) Mostly T-independent (ii) Directly by antigens</td>
<td>Mostly nonpeptidic-self and nonself-antigens</td>
<td>CD1, CD5, CD19, CD20, CD22, CD27, CD9, CD11b, CD43, B20</td>
<td>CD1 (less common)</td>
<td></td>
<td></td>
<td>(i) Natural antibody production (ii) Immunity against infection (iii) Pathogenesis of autoimmune disorders and CLL</td>
<td>[21–28]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cell type</th>
<th>Date of discovery and naming in the first publish</th>
<th>Anatomical locations</th>
<th>Major stimulating and development-effective cytokines</th>
<th>Major transcription factors and molecules needed for development</th>
<th>Major cytokines produced by cells</th>
<th>Major surface markers</th>
<th>Major functions and pathology</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>NK cells (cytotoxic ILCs)</td>
<td>(i) Kiesling et al. 1975 [29]</td>
<td>(i) Secondary lymphoid tissues</td>
<td>(i) IL-12, IL-15, IL-18</td>
<td>Id2 Tox T-bet E4BP4 Eomes</td>
<td>IFN-γ IL-3 IL-10 TNF-α G-CSF GM-CSF CCL2 CCL3 CCL4 CCL5 XCL-1 IL-8</td>
<td>(i) Cytokine receptors&lt;sup&gt;2&lt;/sup&gt; (ii) Chemokine receptors&lt;sup&gt;2&lt;/sup&gt; (iii) Adhesion molecules&lt;sup&gt;3&lt;/sup&gt; (iv) Activating receptors&lt;sup&gt;4&lt;/sup&gt; (v) Inhibitory receptors&lt;sup&gt;5&lt;/sup&gt;</td>
<td>(i) Innate responses against viral infections (ii) Immune surveillance against tumors</td>
<td>[29–35]</td>
</tr>
<tr>
<td></td>
<td>(ii) Herberman et al. 1975 [30]</td>
<td>(ii) Blood (iii) Mucosal tissues (iv) BM and thymus (less common)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>(i) IL-2, IL-21</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rorγ&lt;sup&gt;+&lt;/sup&gt; ILCs</td>
<td>First subset: Mebius et al. 1997 [36]</td>
<td>(i) Fetal lymphoid organs (ii) Tonsils, intestines, spleen, Peyer's patches</td>
<td>(i) IL-1β, IL-23 (ii) IL-7</td>
<td>Rorγ Id2 Tox AhR Notch2 (just in adults)</td>
<td>IL-17 IL-22 IL-2 IL-13 GM-CSF TNF-α LT CXCL-18</td>
<td>(i) In all subsets: CD127 (IL-7Rα), CD161, CD117 (c-kit), OX40L, CD30L</td>
<td>(i) Lymphoid tissue formation (organogenesis) (ii) Tissue repair (iii) In innate immunity against bacterial and yeast infections (iv) Triggering of IgA production independently from T cells (v) Mucosal immunity&lt;sup&gt;6&lt;/sup&gt; (vi) Mucosal homeostasis&lt;sup&gt;7&lt;/sup&gt; (vii) Intestine and cancer pathology&lt;sup&gt;8&lt;/sup&gt;</td>
<td>[2, 36–39]</td>
</tr>
<tr>
<td>Cell type</td>
<td>Date of discovery and naming in the first publish</td>
<td>Anatomical locations</td>
<td>Major stimulating and development-effective cytokines</td>
<td>Major transcription factors and molecules needed for development</td>
<td>Major cytokines produced by cells</td>
<td>Major surface markers</td>
<td>Major functions and pathology</td>
<td>Reference</td>
</tr>
<tr>
<td>-------------------</td>
<td>--------------------------------------------------</td>
<td>----------------------</td>
<td>--------------------------------------------------------</td>
<td>---------------------------------------------------------------</td>
<td>---------------------------------</td>
<td>----------------------</td>
<td>--------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>Type 2 ILCs (ILC2)</td>
<td>2001, 2002, 2010, 2011 (more detail in Table 3)</td>
<td>(i) FALC (ii) Lungs and gut (iii) mLN (iv) Palatine tonsils (v) Spleen (vi) Liver (vii) Peripheral blood</td>
<td>(i) IL-25, IL-33 (ii) IL-7</td>
<td>Id2</td>
<td>IL-5, IL-13</td>
<td>(i) In human: CRTH2 (GPR44), IL-7Ra, IL-7RB, CD25, ST2</td>
<td>(ii) Tissue homeostasis (iii) Airway inflammation and remodeling</td>
<td>[2]</td>
</tr>
<tr>
<td>Name</td>
<td>Date of discovery and naming in the first publish</td>
<td>Species</td>
<td>Tissue distribution</td>
<td>Cytokines produced by cells</td>
<td>Stimulating and development effective cytokines</td>
<td>Transcription factors and molecules needed for development</td>
<td>Surface phenotype</td>
<td>Functions and pathology</td>
</tr>
<tr>
<td>---------------------</td>
<td>--------------------------------------------------</td>
<td>----------------------</td>
<td>---------------------</td>
<td>-----------------------------</td>
<td>-------------------------------------------------</td>
<td>-----------------------------------------------------------</td>
<td>------------------</td>
<td>---------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Natural helper cells (NHCs)</td>
<td>(i) Fort et al. 2001 [40] (ii) Hurst et al. 2002 [41] (iii) Moro et al. 2010 [42]</td>
<td>Wild-type mouse</td>
<td>FALT Lung</td>
<td>*(i) IL-5, IL-13 *(ii) IL-4, IL-6, IL-2 IFN-γ *(iii) SCF/IL-7 *(iv) TSLP</td>
<td>*(i) IL-25, IL-33 *(ii) IL-2/IL-25 *(iii) SCF/IL-7 *(iv) TSLP</td>
<td>*Id2, GATA-3, Stat-6, c-Maf, Jun-b, T-betlow, ETS-1</td>
<td>Lin&lt;sup&gt;−&lt;/sup&gt;, c-kit (CD117), Sca1 (ly6a), IL-7Rα (CD127), CD44, IL-2Ra (CD25), ST2 (IL-33R), CD43, CD69, CD90.2 (Thy1.2), Flt3</td>
<td>(i) Nematode expulsion (ii) Induction of airway pathology following viral infection (iii) Tissue repair following influenza virus infection (iv) B1-B cell renewal (v) IgA production by splenic B cells (vi) Goblet cell hyperplasia</td>
</tr>
<tr>
<td>Nuocytes</td>
<td>(i) Neill et al. 2010 [50]</td>
<td>IL-13-GFP reporter mouse</td>
<td>Intestine mLN Spleen</td>
<td>*(i) IL-5, IL-13 *(ii) IL-4, IL-6, IL-10 *(iii) IL-2, GM-CSF *(iv) CCL3 (MIP1α)</td>
<td>*(i) IL-25, IL-33 *(ii) IL-7</td>
<td>*Id2, Notch-1, RoR-α, GATA-3, c-Maf, Stat-6, Jun-b</td>
<td>Lin&lt;sup&gt;−&lt;/sup&gt;, c-kit&lt;sup&gt;+/−&lt;/sup&gt;, CD44, MHC II, Sca1, IL-12RB, IL-7Ra&lt;sup&gt;+/−&lt;/sup&gt;, IL-17Ra, ICOS (CD278), Klrk1, ST2&lt;sup&gt;+/−&lt;/sup&gt;, IL-10RB, IL-17RB (IL-25R), CD45, CD90.2, IL-27R (wxs1), ICAM-1, ICAM-2, CCR9, CXCR4, CXCR6, B7 integrin</td>
<td>(i) Nematode expulsion (ii) Increase in goblet cell mucin (iii) Increase in T-cell response</td>
</tr>
<tr>
<td>Name</td>
<td>Date of discovery and naming in the first publish</td>
<td>Species</td>
<td>Tissue distribution</td>
<td>Cytokines produced by cells</td>
<td>Stimulating and development-effective cytokines</td>
<td>Transcription factors and molecules needed for development</td>
<td>Surface phenotype</td>
<td>Functions and pathology</td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>--------------------------------------------------</td>
<td>----------------------------------------------</td>
<td>--------------------------------------------</td>
<td>-----------------------------</td>
<td>-----------------------------------------------</td>
<td>----------------------------------------------------------</td>
<td>-----------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>Innate helper2 (Ih2) cells</td>
<td>(i) Price et al. 2010 [53]</td>
<td>IL-13-GFP and IL-4-GFP reporter mouse</td>
<td>Broad, mostly in lung, spleen, mLN, and liver</td>
<td>(i) IL-5, IL-13</td>
<td>(i) IL-28, IL-33</td>
<td>*Id2, GATA-3, Stat-6, aiolos</td>
<td>Lin^−, c-kit^+/−, Sca1^−, CD45, Il-2Ra, CD90,2, CD44, ST2, CD69</td>
<td>(i) Nematode expulsion (ii) Increase in eosinophils</td>
</tr>
<tr>
<td>Type2 innate lymphoid cells (ILCs2)</td>
<td>(i) Mjösgberg et al. 2011 [55]</td>
<td>Human</td>
<td>(i) Fetal/adult gut and lung (ii) Palatin tonsils (iii) Nasal polyps (iv) Adult peripheral blood</td>
<td>(i) IL-5, IL-13</td>
<td>(i) IL-28, IL-2</td>
<td>*Id2, ETS-1, GATA-3</td>
<td>Lin^−, c-kit^+/−, IL-7Ra, IL-2Ra, ST2, IL-17RB, CD45, CRTH2 (GPR44, CD294) CD161 (NKR-P1A)</td>
<td>(i) Chronic rhinosinusitis</td>
</tr>
<tr>
<td>Multipotent progenitor population 2 (MPP2)</td>
<td>Saenz et al. 2010 [56]</td>
<td>IL-4-GFP reporter mouse</td>
<td>(i) mLN (ii) GALT especially in Peyer’s patches and cecal patch</td>
<td>(i) IL-5, IL-13 (mostly mRNA)</td>
<td>(i) IL-28, IL-1 (mostly mRNA)</td>
<td>*Id2, c-Maf^+/−, GATA-3^−, Stat-6^−, CD62L^−, CD34^−, CD161^−, MHC II</td>
<td>(i) Nematode expulsion (ii) Increase in goblet cell mucin (iii) Increase in T-cell response</td>
<td>[43–45, 52, 56]</td>
</tr>
</tbody>
</table>

* The most important
** GFP− cells expressed MHC II after cultivation with a combination of IL-3/SCF.

mice, Yang et al. indicated that NHCs were derived from bone marrow lymphoid progenitors [46]. In this study, lymphoid but not myeloid-erythroid progenitors were able to give rise to natural helper cells in vivo. The cytokine receptor Flt3, which is needed for the efficient generation of bone marrow lymphoid progenitors, is a key factor for NHC development [46]. There is little doubt regarding the derivation of ILC and ILC2 families from common lymphoid progenitors. As described in Section 3 and Table 2, ILC2 populations belong to the innate lymphoid cell (ILC) family along with two other members: NK cells and RoRγt+ ILCs. They all share a phenotypic (lymphoid) homology and a common dependence on transcription repressor Id2 and the yc chain of the IL-2 receptor [2]. It seems likely then that these three ILC family members derive from a common precursor distinct from the B cell/T cell precursor and that all of those precursors in turn derive from a common lymphoid progenitor. In other words, CLP may give rise to several distinct progenitors, one with a potential to change into ILC subsets and another with a potency to differentiate to ILC2 subsets. This has been supported by the finding that Id2 overexpression in hematopoietic precursors inhibits B cell, T cell, and plasmacytoid dendritic cell development while promoting ILC differentiation (reviewed in [57]). In fact, Id2, in association with transcription factor (TF) Tox, commits CLP to a common ILC progenitor that is capable of development towards type 2 ILCs and RoRγt+ ILCs in the presence of RORα/GATA-3 and RORγt/AhR, respectively [57].

MPPtype2 cells are dependent on IL-3 and stem cell factor (SCF) for in vitro survival growth, and expansion [56]. SFC and IL-7 are required for survival, and IL-2, with or without IL-25, is necessary for proliferation in NHC cultures [42]. Survival, and expansion of nuocytes is IL-7 and IL-33 dependent [50]. All ILC2 family members activate and release IL-5 and IL-13 in response to IL-25, IL-33, and helminth infections [42, 50, 53, 55, 56]. NHC and nuocytes are more IL-7 dependent (for development and survival) than other ILC2 family members. Human ILCs2 can expand and produce type 2 cytokines in response to IL-2/IL-25 or IL-2/IL-33 combinations [55]. Transcription repressor Id2 has an important role in the development of all ILC2 family members [2]. This raises the possibility that one of the E proteins, which are Id2 blocker ligands, may arrest ILC2 development. The transcription factor RoRyt, which has a pivotal role in RoRyt+ ILCs development, has no definite role in mouse ILC2 generation but expressed in low abundance by human ILC2 [55]. Other transcription factors involved in ILC2 development are c-Maf, Jun-b, and T-bet for NHCs [42] and Gata-3 and STAT-6 for NHCs, nuocytes, and Ihl2 cells [50, 53]. Ihl2 cells are also aiolosdependent. Aiolos is a Th2 transcription factor [53]. It has recently been shown that nuocytes are dependent on Notch1 and Rora [52]. MPPtype2 cells express no or low transcripts of STAT-6, GATA-3, and ETS-1 transcription factor, in addition to GATA-3 and STAT-6. These transcription factor pathways (STAT-6, GATA-3, and ETS-1) may contribute to ILC2 proliferation, and Th2-type responses were seen in Alternaria-induced asthma [47].

4.4. Biologic Functions. It is now obvious that the most important role of ILC2 is type 2 cytokine production, especially IL-5 and IL-13. The function of cell surface markers and other ILC2 molecules in cell-cell interactions is not fully understood.

4.4.1. Crosstalk with Other Cell Types. ILCs2 are involved in cell-cell interactions with other hematopoietic cells. FALC resident NHCs can induce peritoneal B1-B cells to renew themselves and also splenic B cells to produce IgA [42]. Inducible costimulator (ICOS), an important factor in germinal center formation, is highly expressed on ILCs2, especially on nuocytes, where ILCs2 can interact with ICOS ligand (ICOSL) on B cells. However, the role of ILCs2 in B cell regulation has not yet been fully elucidated [50]. There may be a dialogue between ILCs2 and T cells, based on experimental studies. There is evidence that ILCs2 are able to trigger and promote Th2 cells, and in turn Th2 cells support ILCs2 [42]. Mice with a deficiency in IL-17RB, a part of IL-25R, show a reduction in frequency of both ILC2- and IL-13-producing T cells. ILCs2 adoptive transfer to such mice rehabilitates antigen-specific IL-13 production by T cells [42]. On the other hand, although the number of ILCs2 was increased in RAG−/− mice infected with Nippostrongylus brasiliensis, they are not maintained. So ILCs2 are necessary to mount a Th2 response, and in turn, Th2 cells support IL-5 and IL-13 production by ILCs2. Saenz et al. demonstrated that MPPtype2 cells can present antigens and also promote Th2 responses [56]. Nuocytes express MHC-II, so they could hypothetically present antigens to T cells [50].

ILCs2 can also interact with nonhematopoietic cells. Human ILCs are abundant in fetal gut, even before microflora colonization. Although the function of ILCs has not been elucidated in gut formation and homeostasis, their presence suggests they may have a potential role [55]. ILCs constitutively express IL-13 transcripts, and this cytokine may promote fetal gut formation. In two separate studies, it has been shown that ILCs2 interact with lung cells and are involved in in lung tissue protection and repair [46, 57]. Influenza virus-induced airway hyperresponsiveness (AHR) was exaggerated in ILC2 depletion, as shown by Monticelli et al. [48]. ILCs2 can reduce AHR through production of amphiregulin, a member of the epidermal growth factor (EGF) family, because this substance can affect epithelial cell integrity, lung function, and airway remodeling [48]. Hence, the production of tissue-protective materials could be one the mechanisms of ILC2 involvement in lung tissue homeostasis. Production of these wound-healing molecules has also been demonstrated for alveolar macrophages [49].

4.4.2. Immunity against Helminth Infections. Type 2 immune responses are important in defense against all helminth infections. The roles of IL-25 and IL-33 in immune responses against helminths have been demonstrated. ILCs2 are considered to be major IL-25 and IL-33 responders, so these
cytokines stimulate ILCs2 to produce the type 2 cytokines IL-5 and IL-13 [2].

IL-13 induces production of resistin-like molecule b (RELMb), an antinematode protein [2]. IL-13 can also trigger the secretion of IgE [58]. IL-5 induces eosinophil differentiation and recruitment from bone marrow [58]. Taken together, the above studies suggest ILCs2 could be the executive arms of IL-25 and IL-33 on helminth immunity. This idea has been proved by the study through which transfer of purified in vitro-cultured ILCs2 to IL-25 and IL-33-deficient mice rescued them from *N. brasiliensis* infection. In experiments by Yasuda et al., IL-33 activated ILCs2 populated in lungs and triggered pulmonary eosinophilia in *Strongyloides venezuelensis*-infected mice even in absence of adaptive immune cells [59].

In general, cooperation of ILCs2 and Th2 cells leads to recruitment and activation of other type 2 “immune franchise” including eosinophils, basophils, mast cells, and IgE-producing B cells, as well as goblet cell hyperplasia, resulting in effective immune responses against helminths [2].

4.4.3. Airway Pathology. In type 2 response-related disorders, type 2 immune cells and cytokines cause tissue damage and pathologic inflammatory conditions [60]. Airway inflammation and damage are the most relevant type 2 pathologies that result from airway allergy and asthma. The role of ILCs2 in type 2-related diseases can be considered from two points of view. (1) IL-25 and IL-33 are type 2 cytokines; their significant roles in type 2 airway allergy have been clearly demonstrated [61–65]. The study of their molecular mechanisms is an attractive area for basic and clinical research. ILCs2 as the major IL-25/IL-33 responsive cells could be considered as downstream effectors of these cytokines [54, 66]. (2) Regarding IL-5 and IL-13 as potent type 2 inducers, it is reasonable to propose important roles for ILCs2 in type 2 airway pathologies such as allergy and asthma [48, 52, 67–70].

In this section, we review the significant roles of IL-25 and IL-33 and their main responder cells, ILCs2, in airway allergic diseases and asthma.

IL-33 is a newly identified member of the IL-1 cytokine family [71]. It has a heterodimeric receptor, IL-33R, consisting of ST2 (also known as IL-1RL1, T1, DER4, IL-1R4, and Fit-1) and IL-1R accessory protein (IL-1RAcP) [71]. IL-33 is produced by a variety of cells and tissues including human and mouse lung tissue, lung stromal cells, airway epithelial cells, airway smooth muscle cells, and alveolar macrophages (reviewed in [61, 62]). IL-33-activated type 2 “immune franchise” produces a wide spectrum of type 2 cytokines (reviewed in [63]). Three independent tools have been used to disclose the role of IL-33 in promoting airway allergy and asthma [63]; these are (1) genetic studies: in the case of IL-33 and/or ST2 gene polymorphisms or genomewide association studies (GWAS), (2) evaluations of IL-33/ST2 cellular gene expression and intracellular signaling pathways in allergic and asthmatic mice, for example, by ST2 blockage or IL-33 inhibition, and (3) study of IL-33-defective mice, and also evaluation of IL-33 administration to such mice. Results of these studies demonstrated that IL-33 increases in clinical and experimental models of asthma so that its levels correlate with disease severity and that IL-33 and/or ST2 blockage reduce symptom severity [61–63]. IL-33 can induces anaphylactic shock when it is associated with IgE [61]. Another example of the significant role of IL-33 in allergic/asthmatic reactions is that IL-33 was overexpressed in skin cells of patients with atopic asthma, and degradation of IgE-primed skin mast cells was mediated by IL-33. IL-33 administration also induced AHR and goblet cell hyperplasia even in the absence of adaptive immunity [61]. It has been shown that IL-33 localizes to the nucleus and is probably released from damaged cells and tissues, because it is seen in allergen-mediated airway pathology. Hence, IL-33 may act as a nuclear alarm for innate immunity after damage to, or infection of, epithelial barriers [64]. Therefore, in a general view, the active role of IL-33 in triggering of type 2 immune responses has dual outcomes: (1) a protective one in the case of infections by promoting tissue repair and damage containment mechanisms and (2) a detrimental one in appreciation of type 2 immune-related diseases, marked airway allergic inflammation, and asthma [62].

IL-25 is a member of the IL-17 family (IL-17E) that binds to its heterodimeric receptor (IL-25R), IL-17RA/IL-17RB [40]. IL-25 is another newly identified type 2 cytokine that induces type 2-related disorders [40]. In a murine model of atopic dermatitis, dermal dendritic cell-derived IL-25 could demolish epithelial barrier function through both Th2-response induction and inhibition of keratinocytes to filaggrin, a necessary factor for skin barrier development [65].

Several studies indicated ILCs2 in allergic reactions and asthma as major responders to IL-25 and IL-33 and significant inducers of type 2 responses. In two studies [54, 67], virus- and glycolipid-induced AHR activated macrophages to produce IL-33, which in turn led to accumulation of ILCs2 and type2 cytokine-mediated exacerbation of inflammation. These studies showed that depletion of ILCs2 with anti-Thy1 antibodies significantly reduces virus-induced AHR. Furthermore, adoptive transfer of ILCs2 to IL-13−/− mice restored AHR in both virus- and glycolipid-induced asthma. These studies show that ILCs2 can induce lung pathology even if they were the only source of IL-13. In the virus-induced AHR model by Chang et al., two functionally distinct ILCs2 were speculated to exist in the lung [67]: (1) ST2+ cell types; probably natural helper cells (NHCs) that produce IL-13 in response to IL-33 and contribute to virus-induced AHR. These cells have no impact on T-cells mediated allergen-induced asthma and therefore are not necessary for allergen-specific Th2 differentiation and (2) IL-17RB+ lung-resident cells, probably nuocytes, that trigger Th2 responses in a manner dependent on IL-33 and/or IL-25. Recently, Wolternik et al. have shown that ILCs2 are resident cells in lungs and mediastinal lymph nodes [68]. Intranasal administration of IL-33 and IL-25 caused an asthmatic phenotype in mice by increased accumulation of ILCs2 in lungs and bronchoalveolar fluids. Using IL-5 reporter mice, a non-T lymphoid cell type was recognized
in the lung with similar phenotype and cytokine patterns, but not identical to ILCs2 [69]. These cells produce IL-5 and recruit and maintain eosinophils to the lungs in response to IL-25, and more effectively, to IL-33.

The link between ILCs2 and the adaptive immune system has been addressed. In OVA and house dust mite- (HDM-) induced experimental asthma, ILCs2 are the main source of IL-5 and IL-13 production. This research team [68] also revealed that ILC2 activation could occur even in absence of T cells in RAG−/− mice. In support of this finding, Barlow et al. showed that ILC2, and not Th2 cells, are the main actors of airway inflammations, in OVA-induced experimental asthma [70]. In OVA-induced asthma there was a similar number of Th2 cells and ILCs2 in lung, perhaps because of a need for T-cell-mediated specific recognition of OVA peptides. Interestingly, even in this asthmatic model, ILCs2 were the main source of IL-5, but both cell types produced equal amounts of IL-13 [68, 70]. In experimental ova- and protease-induced asthma models, Oboki et al. demonstrated that IL-33 is an amplifier of innate rather than acquired immune responses [72]. In a Hammad et al. study, HDM-induced asthma activated airway epithelial cells in an LPS-TLR4 interaction-dependent manner [73]. This activation in turn increased the production of IL-33, IL-25, and thymic stromal lymphopoietin (TSLP); raising the possibility that resident ILCs2 might be activated by these stroma-derived cytokines in HDM-induced asthma. Halim et al. showed a similar ILC2 activation in a protease allergen-induced asthma model [66]. Therefore, the role of ILCs2 in asthma seems to be as a primary translator of allergen-induced stroma-derived signals, which result in type 2 cytokine production and pathology by these cells. These massive stimulations subsequently will include the adaptive immune system as well. In conditions of T-cell activation, as in OVA-induced asthma, for example, ILCs2 seem to be downstream amplifiers of inflammation from T cells. This finding was confirmed by a recent study in which ILC2 activation by intranasal administration of papain, a protease allergen, temporarily mediated IL-9 production [74]. IL-9 production depended only on acquired immunity-derived IL-2, suggesting a functional link, and possible dependency, of these innate cells to the adaptive immune system. The dependency of ILCs2 to adaptive immunity both for cytokine production [74] and survival/maintenance (Section 4.3) could alter the conventional thinking that lack of adaptive immune cells can only affect adaptive sources of cytokine production.

5. Concluding Remarks and Future Directions

ILCs2 are a heterogeneous subset of the ILC family that can be subdivided on the basis of surface phenotype and cytokine production patterns. The origin of ILCs2 has not been conclusively identified. It is not fully understood whether ILCs2 are truly different subsets with distinct development pathways or different responses of a single plastic cell type responding to environmental conditions and stimuli. Hence, they could be considered as members of the “type 2 franchise” that collectively mediate type 2-related airway pathology, such as allergy and asthma [60]. Whether ILCs2 can lead to this pathology alone or only following involvement of adaptive T cells remains to be fully understood. ILCs2, as a main source of type 2 cytokines, have a pivotal role in triggering other innate and acquired immune cells. Studies of ILCs2 by depletion or adoptive transfer have increased our understanding of the clinical manifestations of allergy and asthma. The need to understand ILC2 activators, signal transducing molecules, affected targets, and their mechanisms is urgent. In consideration of that, most of our knowledge about ILCs2 biology and function is based on in vitro and animal model studies. The question as to whether human ILCs2 are as important as animal ones in triggering type 2 responses and pathology remains to be answered and is an exciting area of future investigation.

Acknowledgment

This work was supported by the Research Council of Mashhad University of Medical Sciences (MUMS), Mashhad, Iran.

References


F. Chen, Z. Liu, W. Wu et al., “An essential role for TH2-type...”

L. A. Monticelli, G. F. Sonnenberg, M. C. Abt et al., “Innate...”

A. E. Price, H. E. Liang, B. M. Sullivan et al., “Systemically...”

J. Barlow and A. N. J. McKenzie, “Nuocytes: expanding the...”


J. L. Barlow, A. Bellosi, C. S. Hardman et al., “Innate IL-13-...”

J. L. Barlow, A. Bellosi, C. S. Hardman et al., “Innate IL-13-...”

J. Mjøsberg, S. Trifari, N. K. Crellin et al., “CRTH2 and...”

S. A. Saenz, M. C. Siracusa, J. G. Perrigoue et al., “IL25 elicits...”

S. A. Saenz, M. C. Siracusa, J. G. Perrigoue et al., “IL25 elicits...”

J. Mjøsberg, J. Bernink, C. Peters, and H. Spits, “Transcriptional...”

M. Kurowska-Stolarska, P. Kewin, G. Murphy et al., “IL-33 induces...”

K. Yasuda, T. Mutoa, T. Kawagoe et al., “Contribution of...”

Submit your manuscripts at
http://www.hindawi.com